文献速递慢性肾脏病

慢性肾脏病中的心脏生物标志物:信号还是噪声?

Cardiac Biomarkers in Chronic Kidney Disease: Signal or Noise?
PubMed 文献 · Clin J Am Soc Nephrol · 2025-10-31

本文综述慢性肾脏病患者中心脏生物标志物的应用现状,讨论其作为心血管风险评估与治疗反应监测工具的潜力。作者指出肾功能下降与肾脏特异性危险因素会影响标志物循环水平,使结果解读困难,并评估NT-proBNP、肌钙蛋白及ST2、半乳糖凝集素-3、GDF-15等是否满足可靠性与临床效用标准。

要点

  • 肾功能下降影响心脏标志物循环水平,解读需谨慎
  • NT-proBNP与肌钙蛋白是CKD中常用但解读困难的心脏标志物
  • 新型标志物如ST2、半乳糖凝集素-3、GDF-15尚待验证其CKD中的临床效用

核心结论

  • 多种心脏生物标志物已广泛可用并常规用于临床,但许多尚未转化为CKD患者的常规临床诊疗。

研究设计与样本

  • 综述,概述CKD中心脏生物标志物的现状,重点讨论NT-proBNP、肌钙蛋白及ST2、半乳糖凝集素-3、生长分化因子-15。

主要发现

  • 生物标志物可作为心血管病理生理机制的替代指标,甚至被用作临床试验终点。
  • 生物标志物的总体效用取决于检测的可靠性与一致性、所代表信息的内容及其影响临床诊疗的能力。
  • 肾功能清除下降及肾脏特异性危险因素可影响标志物循环水平,使CKD患者中标志物解读具有挑战性。

临床怎么用

  • 在CKD患者中解读心脏生物标志物时需考虑肾功能下降对循环水平的影响。
  • 选用标志物应评估其检测可靠性、信息内容及对临床诊疗的实际影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cardiac biomarkers can provide an easily accessible and noninvasive method of assessing aspects of a patients' underlying cardiovascular health. In doing so, they can serve both as a screening tool for evaluating patients' risk for cardiovascular events and a management tool for evaluating response to directed treatment. Biomarkers serve as surrogates for mechanistic pathways that are relevant for cardiovascular pathophysiology and, as such, have even been used as clinical trial end points. The overall utility of a biomarker is dependent on the reliability and consistency of the assay, the content of the represented information, and its ability to affect clinical care. Several cardiac biomarkers are widely available and routinely used in clinical practice. However, despite significant research into cardiac biomarkers, many have not been translated into routine clinical care of persons with CKD. Interpretation of cardiac biomarkers can be challenging given the possible effects of reduced kidney clearance as well as the contribution of kidney-specific risk facts on circulating levels of the biomarkers. Here, we will provide an overview of the current state of cardiac biomarkers in CKD and whether the biomarker meets the above criteria specifically in persons with CKD. We will focus on several widely used cardiac biomarkers ( N -terminal pro-B-type natriuretic peptide and troponin) as well as select newer promising cardiac biomarkers (soluble suppression of tumorigenicity 2, galectin-3, and growth differentiation factor-15).

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. de Wolski K, Bansal N. Cardiac Biomarkers in Chronic Kidney Disease: Signal or Noise? Clin J Am Soc Nephrol. 2025. PMID: 41171316. doi:10.2215/CJN.0000000947

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。